research MP09-17 METHYLATION OF SRD5A2 IN THE BLOOD AS A NOVEL BIOMARKER TO PREDICT SENSITIVITY TO 5-ARI TREATMENT
SRD5A2 methylation in blood can predict how well someone will respond to finasteride treatment.
Search
for
Sort by
Research
180-210 / 1000+ results 
research The action of diazoxide and minoxidil sulphate on rat blood vessels: a comparison with cromakalim
Diazoxide, minoxidil sulphate, and cromakalim relax rat blood vessels by opening K+ channels, with some differences in their actions.
research Effects of 5-alpha reductase inhibitors on erectile function, sexual desire and ejaculation
5-alpha reductase inhibitors can cause sexual side effects like erectile dysfunction and reduced sexual desire, sometimes lasting after stopping the drug.
research A liquid chromatography/tandem mass spectrometry method for determination of aristolochic acid‐I in rat plasma
A reliable method was developed to measure aristolochic acid-I in rat blood.
research Determination of rat 5α-reductase type 1 isozyme activity and its inhibition by novel steroidal oxazolines
New steroidal compounds moderately block an enzyme related to testosterone conversion, less effectively than finasteride.
research Risks and side effects in the medical management of benign prostatic hyperplasia
Medications for BPH can have significant side effects, so understanding these risks is important for treatment decisions.
research Bladder cancer survival in men using 5-alpha-reductase inhibitors
Using 5-alpha-reductase inhibitors may improve bladder cancer survival in men.
research High-performance liquid chromatographic determination of the enantiomers of the benzoquinolinone LY 191704, a human type 1 5α-reductase inhibitor, in plasma
Researchers developed a method to measure different forms of a drug that could help treat prostate issues and hair loss, and found how these forms behave in animals.
research 5alpha-reductase: history and clinical importance.
5alpha-reductase inhibitors like finasteride and dutasteride effectively treat BPH by reducing DHT, offering symptom relief and potential future uses.
research Abstract A12: Androgen receptor inhibition is involved in Finasteride-reduced AML cell proliferation
Finasteride reduces AML cell growth by inhibiting androgen receptors.
research MP44-04 TRENDS IN 5-ALPHA REDUCTASE INHIBITOR USE BEFORE AND AFTER THE FOOD AND DRUG ADMINISTRATION SAFETY WARNING
Prescriptions for 5-alpha reductase inhibitors dropped significantly after the FDA's safety warning, especially for men with benign prostatic hyperplasia.
research Towards the Development of AgoKirs: New Pharmacological Activators to Study Kir2.x Channel and Target Cardiac Disease
New compounds may help treat heart disease by activating specific potassium channels.
research Adrenolytic and Vasodilator Therapy
New drugs like clonidine and prazosin show promise for treating high blood pressure despite some side effects.
research QSAR Analysis of a Series of Hydantoin‐based Androgen Receptor Modulators and Corresponding Binding Affinities
Researchers developed reliable models to predict how well certain compounds bind to androgen receptors, emphasizing the importance of atomic electronegativity.
research Comparison of clinical trials with finasteride and dutasteride.
Dutasteride reduces DHT more than finasteride, but both drugs improve BPH symptoms similarly.
research Identification of Anabolic Selective Androgen Receptor Modulators with Reduced Activities in Reproductive Tissues and Sebaceous Glands
Two new compounds were found to build bone and muscle without affecting reproductive organs and skin oil glands.
research (379) The Effect of 5-α Reductase Inhibitor on Male Reproductive Function
5-α reductase inhibitors do not significantly affect male reproductive function but may reduce semen volume.
research Membrane androgen receptors may mediate androgen reinforcement
Androgen self-administration might be controlled by membrane receptors, not nuclear ones.
research 52243 AH-001: An Emerging Androgen Receptor Degrader Showing Therapeutic Potential in Addressing Androgenetic Alopecia (AGA)
AH-001 could be a safer and more effective treatment for hair loss.
research Editorial Comment
More men are using medication for benign prostatic hyperplasia, influenced by marketing and FDA approvals.
research Selective androgen receptor modulators (SARMs) have specific impacts on the mouse uterus
GTx-024 and Danazol affect the uterus like DHT, while GTx-007 has little impact.
research 5α-reductase inhibitors impact prognosis of urothelial carcinoma
5α-reductase inhibitors may lower the risk of death from bladder cancer.
research Influence of the alkylsulfonylamino substituent located at the 6-position of 2,2-dimethylchromans structurally related to cromakalim: From potassium channel openers to calcium entry blockers?
New compounds similar to cromakalim were less effective at inhibiting insulin release but improved in solubility and one acted as a calcium entry blocker, not a potassium channel opener.
research Effect of MK-386, a novel inhibitor of type 1 5 alpha-reductase, alone and in combination with finasteride, on serum dihydrotestosterone concentrations in men
research Major role for 5-alpha reductase inhibitors in the aging male
5-alpha reductase inhibitors help treat prostate issues in aging men, but their role in cancer prevention is debated.
research PD02-05 SRD5A2 EXPRESSION IS A PREDICTOR OF RESPONSE TO FINASTERIDE IN THE MTOPS TRIAL
Higher SRD5A2 expression predicts better response to finasteride in treating urinary symptoms.
research Dutasteride reduces alcohol’s sedative effects in men in a human laboratory setting and reduces drinking in the natural environment
Dutasteride makes alcohol less sedating and may lead to less drinking in men.
research An overview on 5α-reductase inhibitors
5α-reductase inhibitors, like Finasteride and Dutasteride, help manage benign prostatic hyperplasia.
research Hydroxysteroid Dehydrogenase (17β -HSD3, 17β-HSD5, and 3α-HSD3) Inhibitors:Extragonadal Regulation of Intracellular Sex Steroid Hormone Levels
Certain inhibitors can potentially treat prostate cancer and other hormone-dependent conditions by controlling sex hormone levels in cells.
research Preliminary pharmacokinetics and metabolism of novel non-steroidal antiandrogens in the rat: Relation of their systemic activity to the formation of a common metabolite
Two non-steroidal antiandrogens, RU 58841 and RU 56187, form a common metabolite at different rates, which may influence their effects; RU 56187 could be used for prostate cancer treatment and RU 58841 for acne treatment.